Compare Stocks: STOK, IOVA, RYTM, and LGND

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IOVA Iovance Biotherapeutics	$14.62 +6.1%	$11.04	$1.76 ▼ $15.37	$6.61B	0.76	15.50 million shs	3.59 million shs
LGND Ligand Pharmaceuticals	$312.28 +1.3%	$294.13	$175.89 ▼ $326.63	$6.23B	1.14	267,034 shs	28,751 shs
RYTM Rhythm Pharmaceuticals	$91.66 +2.4%	$98.89	$74.50 ▼ $122.20	$6.28B	2.01	748,254 shs	59,060 shs
STOK Stoke Therapeutics	$26.26 +3.2%	$28.02	$20.32 ▼ $40.22	$1.69B	1.26	814,163 shs	298,239 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IOVA Iovance Biotherapeutics	-2.20%	-3.03%	+25.27%	+193.19%	+512.44%
LGND Ligand Pharmaceuticals	+1.57%	+3.71%	+2.25%	+4.06%	+64.88%
RYTM Rhythm Pharmaceuticals	+0.22%	+1.41%	-9.31%	-17.19%	-19.01%
STOK Stoke Therapeutics	+1.68%	+2.58%	+2.66%	-13.37%	-21.13%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IOVA Iovance Biotherapeutics	$14.62 +6.1%	$11.04	$1.76 ▼ $15.37	$6.61B	0.76	15.50 million shs	3.59 million shs
LGND Ligand Pharmaceuticals	$312.28 +1.3%	$294.13	$175.89 ▼ $326.63	$6.23B	1.14	267,034 shs	28,751 shs
RYTM Rhythm Pharmaceuticals	$91.66 +2.4%	$98.89	$74.50 ▼ $122.20	$6.28B	2.01	748,254 shs	59,060 shs
STOK Stoke Therapeutics	$26.26 +3.2%	$28.02	$20.32 ▼ $40.22	$1.69B	1.26	814,163 shs	298,239 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IOVA Iovance Biotherapeutics	-2.20%	-3.03%	+25.27%	+193.19%	+512.44%
LGND Ligand Pharmaceuticals	+1.57%	+3.71%	+2.25%	+4.06%	+64.88%
RYTM Rhythm Pharmaceuticals	+0.22%	+1.41%	-9.31%	-17.19%	-19.01%
STOK Stoke Therapeutics	+1.68%	+2.58%	+2.66%	-13.37%	-21.13%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IOVA Iovance Biotherapeutics	2.62	Moderate Buy	$13.20	-9.68% Downside
LGND Ligand Pharmaceuticals	3.00	Buy	$337.89	8.20% Upside
RYTM Rhythm Pharmaceuticals	2.77	Moderate Buy	$142.50	55.47% Upside
STOK Stoke Therapeutics	2.82	Moderate Buy	$44.25	68.48% Upside

Current Analyst Ratings Breakdown

Latest STOK, IOVA, RYTM, and LGND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/16/2026	RYTM Rhythm Pharmaceuticals	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/15/2026	RYTM Rhythm Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$146.00 ➝ $145.00
10/13/2026	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$15.00 ➝ $18.00
10/12/2026	RYTM Rhythm Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$105.00 ➝ $130.00
10/8/2026	RYTM Rhythm Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$155.00 ➝ $159.00
10/8/2026	IOVA Iovance Biotherapeutics	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$6.00 ➝ $11.00
9/30/2026	IOVA Iovance Biotherapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$14.00 ➝ $18.00
9/29/2026	IOVA Iovance Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/29/2026	IOVA Iovance Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$9.00 ➝ $20.00
9/25/2026	LGND Ligand Pharmaceuticals	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight	$345.00

(Data available from 10/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IOVA Iovance Biotherapeutics	$324.97M	20.37	N/A	N/A	$1.76 per share	8.30
LGND Ligand Pharmaceuticals	$268.09M	23.23	$8.08 per share	38.66	$51.68 per share	6.04
RYTM Rhythm Pharmaceuticals	$239.92M	26.18	N/A	N/A	$2.08 per share	44.07
STOK Stoke Therapeutics	$27.59M	61.43	N/A	N/A	$6.17 per share	4.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IOVA Iovance Biotherapeutics	-$390.98M	-$0.73	N/A	N/A	N/A	-89.11%	-40.51%	-31.65%	11/5/2026 (Estimated)
LGND Ligand Pharmaceuticals	$124.45M	$9.35	33.40	37.40	2.43	67.88%	20.06%	11.68%	10/29/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)
STOK Stoke Therapeutics	-$6.89M	-$3.34	N/A	N/A	N/A	-753.60%	-59.36%	-51.46%	10/29/2026 (Estimated)

Latest STOK, IOVA, RYTM, and LGND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	IOVA Iovance Biotherapeutics	-$0.0850	N/A	N/A	N/A	$115.53 million	N/A
11/3/2026	Q3 2026	RYTM Rhythm Pharmaceuticals	-$0.7101	N/A	N/A	N/A	$85.48 million	N/A
10/29/2026	Q3 2026	LGND Ligand Pharmaceuticals	$2.33	N/A	N/A	N/A	$77.00 million	N/A
10/29/2026	Q3 2026	STOK Stoke Therapeutics	-$0.9291	N/A	N/A	N/A	$8.21 million	N/A
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	-$0.11	+$0.0235	-$0.11	$87.83 million	$99.31 million
8/6/2026	Q2 2026	LGND Ligand Pharmaceuticals	$1.97	$2.37	+$0.40	$2.22	$61.30 million	$63.69 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million
8/3/2026	Q2 2026	STOK Stoke Therapeutics	-$0.7950	-$0.93	-$0.1350	-$0.93	$4.89 million	$9.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IOVA Iovance Biotherapeutics	N/A	4.34	3.82
LGND Ligand Pharmaceuticals	1.16	31.18	30.96
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20
STOK Stoke Therapeutics	N/A	7.69	7.69

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IOVA Iovance Biotherapeutics	77.03%
LGND Ligand Pharmaceuticals	91.28%
RYTM Rhythm Pharmaceuticals	N/A
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
IOVA Iovance Biotherapeutics	7.80%
LGND Ligand Pharmaceuticals	5.60%
RYTM Rhythm Pharmaceuticals	5.90%
STOK Stoke Therapeutics	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IOVA Iovance Biotherapeutics	975	452.97 million	417.64 million	Optionable
LGND Ligand Pharmaceuticals	47	19.94 million	18.82 million	Optionable
RYTM Rhythm Pharmaceuticals	414	68.53 million	64.49 million	Optionable
STOK Stoke Therapeutics	170	64.53 million	58.33 million	Optionable

STOK, IOVA, RYTM, and LGND Headlines

Recent News About These Companies

Stoke Therapeutics (STOK) Projected to Post Quarterly Earnings on Thursday

October 24 at 1:41 AM | americanbankingnews.com

Stoke Therapeutics (STOK) Projected to Announce Earnings on Thursday

October 24 at 1:40 AM | marketbeat.com

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates

October 22, 2026 | finance.yahoo.com

STOK - Stoke Therapeutics, Inc.

October 20, 2026 | seekingalpha.com

Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 8.9% - Time to Buy?

October 20, 2026 | marketbeat.com

Reviewing ImageneBio (NASDAQ:IMA) & Stoke Therapeutics (NASDAQ:STOK)

October 20, 2026 | americanbankingnews.com

Stoke Therapeutics: The Market Misread A Key FDA Win

October 19, 2026 | seekingalpha.com

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - October 16, 2026

October 18, 2026 | biospace.comB

Stoke Therapeutics grants 245,920 options on Stoke Therapeutics stock

October 18, 2026 | ad-hoc-news.deA

Assenagon Asset Management S.A. Acquires 52,394 Shares of Stoke Therapeutics, Inc. $STOK

October 18, 2026 | marketbeat.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Has Consensus Target Price of $44.25 According to Brokerages

October 18, 2026 | americanbankingnews.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Has Average Target Price of $44.25

October 18, 2026 | marketbeat.com

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

October 16, 2026 | businesswire.com

Stoke Therapeutics, Inc. Presents Data Supporting Disease-Modifying Potential Of STK-002 In Autosomal Dominant Optic Atrophy At The American Academy Of Ophthalmology 2026 ...

October 13, 2026 | marketscreener.comM

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and AbbVie (ABBV)

October 13, 2026 | theglobeandmail.com

Stoke Therapeutics (NASDAQ:STOK) Shares Down 7.1% - Time to Sell?

October 13, 2026 | marketbeat.com

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO ...

October 12, 2026 | finance.yahoo.com

FDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK)

October 10, 2026 | finance.yahoo.com

Stoke Therapeutics, Inc. Announces Presentations of Data for Stk-002 At the American Academy of Ophthalmology 2026 Annual Meeting

October 6, 2026 | marketscreener.comM

Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of ...

October 6, 2026 | finance.yahoo.com

Stoke Therapeutics (NASDAQ:STOK) Shares Down 5.9% - What's Next?

October 6, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK, IOVA, RYTM, and LGND Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

$14.62 +0.84 (+6.06%)

As of 11:38 AM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Ligand Pharmaceuticals NASDAQ:LGND

$312.28 +3.98 (+1.29%)

As of 11:37 AM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Rhythm Pharmaceuticals NASDAQ:RYTM

$91.66 +2.19 (+2.45%)

As of 11:38 AM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Stoke Therapeutics NASDAQ:STOK

$26.26 +0.80 (+3.16%)

As of 11:38 AM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STOK, IOVA, RYTM, and LGND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STOK, IOVA, RYTM, and LGND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STOK, IOVA, RYTM, and LGND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK, IOVA, RYTM, and LGND Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

Ligand Pharmaceuticals NASDAQ:LGND

Rhythm Pharmaceuticals NASDAQ:RYTM

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STOK, IOVA, RYTM, and LGND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STOK, IOVA, RYTM, and LGND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STOK, IOVA, RYTM, and LGND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK, IOVA, RYTM, and LGND Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

Ligand Pharmaceuticals NASDAQ:LGND

Rhythm Pharmaceuticals NASDAQ:RYTM

Stoke Therapeutics NASDAQ:STOK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools